Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Immunogen Inc

<< Previous

Bullboard Posts

Next >>

Comment by inthnoon Nov 30, 2023 11:05pm

176 Views

Post# 35762695

RE:RE:RE:RE:Immunogen Inc

Trial size does make a different for sure and I have always wondered why they did not continue on to the next stage of the panc trial. It would have been done now and so much more information. Someone had to make the call and for a major reason and it has now been over a year so what would be the reason.

<< Previous

Bullboard Posts

Next >>

Soma Gold poised to extend profitable track record